5 Questions with Smitha Gopal, Managing Director of Techstars AI Health Baltimore

Smitha Gopal is the Managing Director of Techstars AI Health Baltimore. Smitha led and sold Rendia, an engagement software platform that helps 8,000+ providers improve patient outcomes & accelerate revenue growth. Smitha was the EVP of Strategy and Market Development at PatientPoint and the COO of EcoMap. She holds degrees from Wharton and the University of Virginia.

01. What are you looking for in startups for Techstars AI Health Baltimore?

The program thesis is leveraging AI to transform healthcare by improving patient care, access, affordability, and quality. Exceptional founders are those who deeply understand the problem they’re addressing, whether they earned their insights from work in a clinical or industry setting, or from their lived experience as a patient or caregiver. That firsthand knowledge into clinical workflows, reimbursement pathways, provider adoption or patient adherence are the critical inputs to create early traction. Beyond that, we’re drawn to companies that can already point to early customer validation, like a pilot, a design partnership, a signed LOI, or anything that shows that customers are eager and the stated problem is worth solving. Finally, while there is no single profile for successful entrepreneurs, I am eager to work with founders who demonstrate humility, hustle, and honesty. 

02. What are some of the biggest learnings from your career and entrepreneurial journey that you bring to being a Techstars MD? 

The biggest one is knowing your customer deeply. Understanding their pain points and what they are willing to pay to solve them is foundational. It’s too easy to fall in love with your own solutions, but much more important to center on what your customer needs and wants.

The second one is focus. Early in my time leading Rendia, we had a habit of saying yes to almost everything in an effort to delight our customers. But agreeing to so many feature requests and adjacent opportunities spread us too thin. Learning to say no actually helped us fulfill the promises we’d made to our customers and allowed us to scale the business successfully, leading to our exit.  

The third is that every stakeholder in the ecosystem matters, not just the customer. For many healthcare businesses, Rendia included, the customer may be the provider, health system or payer while the patient is the end-user. You need to think about meeting everyone’s needs effectively. An unresolved conflict between stakeholders’ needs will keep the business from finding success. I carried that lens into my time helping scale an ecosystem-focused AI company, EcoMap, and I bring it into this role too: a startup's success depends on how well it serves all key stakeholders all at once.

03. What is your favorite thing about the Baltimore startup scene?

I’ve chosen to call Baltimore home for two decades, and a big part of its appeal to me is the genuine relationships and connections that exist in this community. We welcome founders with open arms and consistently show up to offer support. Baltimore is also a place where you can speak frankly about challenges and setbacks, and be met with empathy, collaboration and problem-solving help.  

What makes Baltimore especially exciting for AI health specifically is the density of serious institutions in one place. We have a world-class ecosystem here: academic medicine, a major regional payer, and leading health systems all within a few miles of each other and willing to work together. Beyond Baltimore city limits, Maryland is home to CMS, FDA and NIH, plus a unique all-payer model that means startups and early customers share common goals. Our network of partners, density of talent and proximity to key regulatory stakeholders make Baltimore the best place in the country to build a healthcare startup.

04. What do our partners bring to the Techstars AI Health Baltimore accelerator?

Our partners are Johns Hopkins, CareFirst BlueCross BlueShield, MedStar Health, the University of Maryland Baltimore, and the University of Maryland Medical System. Collectively, they represent the full ecosystem of payer, health system and provider. More specifically, our partners give founders actual access. That means real clinical environments to pilot and deploy in as well as payer and reimbursement insight to shape go-to-market strategy.

It also means a solid path to drive traction and commercialization. These partners are potential pilot partners, early customers, and champions inside the systems our founders are trying to sell into. For healthcare companies, that kind of access can compress years of relationship-building into months and create the right conditions to scale successfully.

05. What has traditional healthcare investing missed?

Medical research has traditionally excluded women as study participants and underinvested in women's health as a category. The same is true for diseases that disproportionately affect people of color. Without that underlying research, healthcare investors don't have the full picture, and it's hard to correctly size the market or fairly evaluate companies trying to innovate in that space. The fix is to recognize where that structural bias exists and seek diverse perspectives to give us a clearer view.